

(2) Seeking internal review of the order under § 10.75 of this chapter;

(3) Requesting an informal hearing under part 16 of this chapter; or

(4) Requesting review by the Medical Devices Dispute Resolution Panel of the Medical Devices Advisory Committee.

(b) You may obtain guidance documents that discuss these mechanisms from the Center for Devices and Radiological Health's (CDRH's) Web site (<http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHombudsman/default.htm>).

[67 FR 38887, June 6, 2002, as amended at 72 FR 17399, Apr. 9, 2007; 78 FR 18233, Mar. 26, 2013]

Subpart C—Postmarket Surveillance Plan

§ 822.8 When, where, and how must I submit my postmarket surveillance plan?

You must submit your plan to conduct postmarket surveillance within 30 days of the date you receive the postmarket surveillance order. For devices regulated by the Center for Biologics Evaluation and Research, send three copies of your submission to the Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002. For devices regulated by the Center for Drug Evaluation and Research, send three copies of your submission to the Central Document Room, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B, Ammendale Rd., Beltsville, MD 20705-1266. For devices regulated by the Center for Devices and Radiological Health, send three copies of your submission to the Document Mail Center, 10903 New Hampshire Ave., Bldg. 66, rm. G609, Silver Spring, MD 20993-0002. When we receive your original submission, we will send you an acknowledgment letter identifying the unique document number assigned to your submission. You must use this number in

any correspondence related to this submission.

[75 FR 20915, Apr. 22, 2010, as amended at 80 FR 18094, Apr. 3, 2015]

§ 822.9 What must I include in my submission?

Your submission must include the following:

(a) Organizational/administrative information:

- (1) Your name and address;
- (2) Generic and trade names of your device;
- (3) Name and address of the contact person for the submission;
- (4) Premarket application/submission number and device identifiers for your device;
- (5) Table of contents identifying the page numbers for each section of the submission;
- (6) Description of the device (this may be incorporated by reference to the appropriate premarket application/submission);
- (7) Product codes and a list of all relevant model numbers; and
- (8) Indications for use and claims for the device;

- (b) Postmarket surveillance plan;
- (c) Designated person information:
- (1) Name, address, and telephone number; and
- (2) Experience and qualifications.

[67 FR 38887, June 6, 2002, as amended at 78 FR 55823, Sept. 24, 2013]

§ 822.10 What must I include in my surveillance plan?

Your surveillance plan must include a discussion of:

- (a) The plan objective(s) addressing the surveillance question(s) identified in our order;
- (b) The subject of the study, e.g., patients, the device, animals;
- (c) The variables and endpoints that will be used to answer the surveillance question, e.g., clinical parameters or outcomes;
- (d) The surveillance approach or methodology to be used;
- (e) Sample size and units of observation;
- (f) The investigator agreement, if applicable;
- (g) Sources of data, e.g., hospital records;